期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Survivin和Ki-67在卵巢浆液性囊腺癌中的表达及意义 被引量：4

下载PDF
导出
摘要 目的探讨凋亡抑制基因Survivin和核增殖抗原Ki-67在卵巢浆液性囊腺癌中的表达及其与临床病理特征的关系。方法免疫组化采用SP法,观察46例卵巢浆液性囊腺癌和15例囊腺瘤中Survivin和Ki-67的表达,分析其表达与浆液性癌的临床分期和组织学分级的关系。结果①Survivin与Ki-67在卵巢浆液性囊腺癌中的阳性表达率分别为84.8%和78.3%,高于在囊腺瘤中的阳性表达率26.7%和20.0%;并与临床分期及组织学分级有关;②囊腺癌中Survivin和Ki-67表达呈正相关。结论①Survivin在卵巢浆液性囊腺癌中高表达,可能与卵巢癌的发生、发展有关;Ki-67可作为鉴别卵巢良、恶性肿瘤重要指标;②联合检测Survivin和Ki-67可作为卵巢浆液囊腺癌的诊断、评价恶性程度和预后的重要指标。
作者 李俊霞
机构地区 吉林省敦化市医院妇产科
出处 《中国现代药物应用》 2011年第12期21-23,共3页 Chinese Journal of Modern Drug Application
关键词 卵巢浆液性囊腺癌 SURVIVIN KI-67 免疫组化
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oneol Hematol, 2006,60 ( 2 ) : 159 -179.
  • 2Chawla Sarkar M, Bae SI,Reu FJ, et al. Downregnlation of Bcl-2, FLIP or lAPs ( XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ, 2004,30 : 1160-1175.
  • 3Duffy M J, O' Donovan N, Brennan DJ, et al. Survivin: a promisifig tumor biomarker. Cancer Lett ,2007,249 ( 1 ) :49-60.
  • 4宋欢欢,封全灵.卵巢上皮性肿瘤中磷酸化STAT3与Ki67的表达及其临床意义[J].河南医学研究,2008,17(3):210-212. 被引量：2

二级参考文献8

  • 1Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of STAT3 with a decoy oligonucleotide abrogates herd and neck cancer cell growth[ J ]. Proc Natl Acad SciUSA ,2003,100 ( 7 ) :4138-4143.
  • 2Mizoguchi M, Betensky RA, Batchelor TT, et al. Activation of STAT3, MAPK, and A KT in malignant ast rocytic gliomas: cot2 relation wit h EGFR status, tumor grade, and survival. J Neuro2 pat hol Exp Neurol, 2006, 65(12) :1181-1188.
  • 3Levy DE, Darnell J E J r. Stat s: transcriptional control and biological impact. Nat Rev Mol Cell Biol, 2002, 3(9) :651-662.
  • 4Niu G, Wright KL, Hung M, et al. Constitutive STAT3 activity upregulates VEGF expression and tumor angiogenesis [ J]. Oncogene, 2002, 21(13) :2000.
  • 5Sulkowska M, Golaszewska J, Wincewicz A, et al . Leptin 2From Regulation of fat Metabolism to Stimulation of BreastCancer Growth. Pathol Oncol Res, 2006,12(2) :69-72.
  • 6Ni Z, Lou W, Lee So, et al . Selective activation of members of the signal transdueers and activators of transcription family inprostate carcinoma. J Urol, 2002, 167(4) :1859-1862.
  • 7Rosen D G, M ercado U I, Yang G, et al. The role of constitutivelyactive signal transducer and activator of transcrip tion 3 in ovarian tumorigenesis and prognosis[ J]. Cancer,2006,107 ( 11 ) :2730-2740.
  • 8Sehulter C, Duchrow M,Wohlenberg C, et al. Molecular cloing of the cell proliferation associated nuclear antigen defined by antibody Ki67 : A very large rblquitous nulear protein with numerous repeated elements representing a new kind of cell cycle-maintaining protein[J].J Cell Biol,1993,123(3) :513-522.

共引文献1

同被引文献46

  • 1侯振江.基因标志物在肺癌预后监测中的应用[J].临床肺科杂志,2004,9(6):668-669. 被引量：3
  • 2张丽华,侯振江.nm23基因在肿瘤预后监测中的应用[J].中国肿瘤临床与康复,2006,13(1):85-88. 被引量：9
  • 3D'Adamio F, Zollo O, Moraca R,et al. A new dexamethasone-in- duced gene of the leueine zipper family protects T lymphocytes from TCR/CD3-activated cell death [J]. Immunity ,1997 ,7(6): 803-812.
  • 4Redjimi N, Gaudin F, Touboul C,et al. Identification of glucocor- ticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer [J].Molecular Cancer, 2009,8(1):1-15.
  • 5Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen asso- ciated with cell proliferation[J]. Int J Cancer ,1983,31(3): 13-20.
  • 6Havrilesky L,Darcy M,Hamdan H. Prognostic significiane of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer:a Gynecologic Oncology Group Study[J].Journal of Clinical Oncology,2003,(20):3814-3825.
  • 7Hogdall EV,Christensen L,Hogdall CK. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas[J].Acta Pathologica,Microbiologica Et Immunologica Scandinavica,2008,(05):400-409.
  • 8Kupryjanczyk J,Szymanska T,Madry R. Evaluation of clinical significance of TP53,BCL-2,BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen[J].British Journal of Cancer,2003,(06):848-854.
  • 9Yasui K,Mihara S,Zhao C. Alteration in copy numbers genes as a mechanism for acquired drug resistance[J].Cancer Research,2004,(04):1403-1410.
  • 10Liguang Z,Peishu L,Hongluan M. Survivin expression in ovarian carcinoma[J].Eep Oncol,2007,(02):121-125.

引证文献4

二级引证文献6

中国现代药物应用
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部